1,601,527 Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR) Bought by Great Point Partners LLC

Great Point Partners LLC bought a new stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,601,527 shares of the company’s stock, valued at approximately $12,668,000. Voyager Therapeutics accounts for approximately 2.4% of Great Point Partners LLC’s portfolio, making the stock its 19th biggest position. Great Point Partners LLC owned approximately 2.94% of Voyager Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ameritas Investment Partners Inc. lifted its stake in shares of Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the period. Plato Investment Management Ltd purchased a new stake in Voyager Therapeutics during the first quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. raised its position in Voyager Therapeutics by 104.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock worth $97,000 after acquiring an additional 5,311 shares during the period. SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth $85,000. Finally, ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics during the 1st quarter valued at $101,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $6.10 on Tuesday. The stock has a fifty day simple moving average of $7.23 and a two-hundred day simple moving average of $8.06. Voyager Therapeutics, Inc. has a 52-week low of $5.97 and a 52-week high of $11.72. The firm has a market capitalization of $331.80 million, a PE ratio of -122.00 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. During the same period in the previous year, the firm earned ($0.51) EPS. On average, sell-side analysts forecast that Voyager Therapeutics, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on VYGR shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, August 20th. Wedbush decreased their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $17.83.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.